Bromocriptine oral tablet is a generic drug precribed to treat various conditions including Parkinson’s disease, hormone-related disorders, and type 2 diabetes. It’s also available as brand-name drugs ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with type 2 diabetes may have a new treatment ...

Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of ...

Review the side-effects of Bromocriptine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended restricted use of bromocriptine-containing medicines to inhibit lactation after childbirth ...

In obese, insulin-resistant animals, treatment with the dopamine D2 receptor (D2R) agonist bromocriptine causes reversion to a lean, insulin-sensitive state. Kok and colleagues, therefore, studied the ...

Please provide your email address to receive an email when new articles are posted on . Quick-release bromocriptine is a new formulation of bromocriptine mesylate that the FDA approved in May 2009 for ...

Bromocriptine activates post-synaptic dopamine receptors. The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a ...

Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress ...

Bromocriptine (Polodyl) is a dopamine agonist, prescribed for Parkinson’s disease either alone or with other medications. It is also used for galactorrhoea (abnormal milk production), hypogonadism ...

Zydus Cadila is recalling over 14,800 bottles of Bromocriptine Mesylate capsules manufactured by Cadila Healthcare on account of out of specification results in the US market. According to information ...